Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis

• Published in: Frontiers in psychiatry Vol. 13; p. 877867
• Main Authors: Olivares, José Manuel, Fagiolini, Andrea
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 28.04.2022
• Subjects: antipsychotics; aripiprazole once-monthly (AOM); clinical practice; long-acting injectables; persistence; Psychiatry; schizophrenia; antipsychotics; aripiprazole once-monthly (AOM); clinical practice; persistence; long-acting injectables; schizophrenia
• ISSN: 1664-0640; 1664-0640
• DOI: 10.3389/fpsyt.2022.877867

One of the most significant risk factors for relapse and hospitalization in schizophrenia is non-adherence to antipsychotic medications, very common in patients with schizophrenia. The aim of this analysis was to evaluate the treatment persistence to aripiprazole once-monthly (AOM) and the factors affecting it in the pooled population of two similar studies performed previously in two different European countries. Pooled analysis of two non-interventional, retrospective, patient record-based studies: DOMINO and PROSIGO. Both analyzed treatment persistence after starting AOM treatment in the real-world setting. The primary variable was persistence with AOM treatment during the first 6 months after treatment initiation. A multivariate Cox regression model was used to evaluate the influence of several baseline characteristics on the persistence. The study population comprised 352 patients included in the two studies, DOMINO ( = 261) and PROSIGO ( = 91). The overall persistence with AOM treatment at the end of the 6-month observation period was 82.4%. The multivariate analysis showed that patients with "secondary school" level of education present a 67.4% lower risk of discontinuation within 6 months after AOM initiation when compared with "no/compulsory education patients" ( = 0.024). In addition, patients with an occupation present a 62.7% lower risk of discontinuation when compared with unemployed patients ( = 0.023). Regarding clinical history, patients with a Clinical Global Impression-Severity scale (CGI-S) score ≤3 present a 78.1% lower risk of discontinuation when compared with patients with a CGI-S score ≥6 ( = 0.044), while patients with a time since schizophrenia diagnosis ≤8.4 years present a 52.9% lower risk of discontinuation when compared with the rest of patients ( = 0.039). The AOM persistence rate observed in this study was 82.4%, which was higher than that reported in clinical trials, aligned with other real-life studies and higher than reported for other long-acting injectable antipsychotics. The persistence rate was high in complex patients, although patients with higher level of education, active occupation, lower initial CGI-S score and shorter time since the diagnosis of schizophrenia appear to be more likely to remain persistent with AOM during the 6 months after initiation.